Epigenetic reversion of breast carcinoma phenotype is accompanied by changes in DNA sequestration as measured by AluI restriction enzyme

American Journal of Pathology

Volumn 170, Issue 5, 2007, Pages 1739-1749

  Sandal, Tone ^a   Valyi Nagy, Klara ^a   Spencer, Virginia A ^b   Folberg, Robert ^a   Bissell, Mina J ^b   Maniotis, Andrew J ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; BUCLADESINE; CYCLIC AMP DERIVATIVE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; CYCLIC AMP; DNA; RESTRICTION ENDONUCLEASE;

ACINAR CELL; ALU SEQUENCE; ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CARCINOGENESIS; CELL AGGREGATION; CELL PERMEABILIZATION; CELL STRUCTURE; CONTROLLED STUDY; DNA SEQUENCE; EPIGENETICS; EPITHELIUM CELL; GENETIC EPIGENESIS; HUMAN; HUMAN CELL; MICROENVIRONMENT; PHENOTYPE; POLARIZATION; PRIORITY JOURNAL; BREAST TUMOR; CELL TRANSFORMATION; CONFOCAL MICROSCOPY; CULTURE TECHNIQUE; FEMALE; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; METABOLISM; TUMOR CELL LINE; ULTRASTRUCTURE;

BREAST NEOPLASMS; CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; CYCLIC AMP; DNA RESTRICTION ENZYMES; DNA, NEOPLASM; EPIGENESIS, GENETIC; FEMALE; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; MICROSCOPY, CONFOCAL; PHENOTYPE;

EID: 34250829120     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.2353/ajpath.2007.060922     Document Type: Article

References (44)

1. Maniotis AJ, Valyi-Nagy K, Karavitis J, Moses J, Boddipali V, Wang Y, Nunez R, Setty S, Arbieva Z, Bissell MJ, Folberg R: Chromatin organization measured by AluI restriction enzyme changes with malignancy and is regulated by the extracellular matrix and the cytoskeleton. Am J Pathol 2005, 166:1187-1203
2. Krystosek A, Puck TT: The spatial distribution of exposed nuclear DNA in normal, cancer, and reverse-transformed cells. Proc Natl Acad Sci USA 1990, 87:6560-6564
3. Puck TT, Webb P, Johnson R: Cyclic AMP and the reverse transformation reaction. Ann NY Acad Sci 2002, 968:122-138
4. Weaver VM, Petersen OW, Wang F, Larabell CA, Briand P, Damsky C, Bissell MJ: Reversion of the malignant phenotype of human breast cells in three-dimensional culture and in vivo by integrin blocking antibodies. J Cell Biol 1997, 137:231-245
5. Wang F, Weaver VM, Petersen OW, Larabell CA, Dedhar S, Briand P, Lupu R, Bissell MJ: Reciprocal interactions between betal-integrin and epidermal growth factor receptor in three-dimensional basement membrane breast cultures: a different perspective in epithelial biology. Proc Natl Acad Sci USA 1998, 95:14821-14826
6. Lelievre SA, Weaver VM, Nickerson JA, Larabell CA, Bhaumik A, Petersen OW, Bissell MJ: Tissue phenotype depends on reciprocal interactions between the extracellular matrix and the structural organization of the nucleus. Proc Natl Acad Sci USA 1998, 95:14711-14716
7. Weaver VM, Lelievre S, Lakins JN, Chrenek MA, Jones JC, Giancotti F, Werb Z, Bissell MJ: Beta4 integrin-dependent formation of polarized three-dimensional architecture confers resistance to apoptosis in normal and malignant mammary epithelium. Cancer Cell 2002, 2:205-216
8. Wang F, Hansen RK, Radisky D, Yoneda T, Barcellos-Hoff MH, Petersen OW, Turley EA, Bissell MJ: Phenotypic reversion or death of cancer cells by altering signaling pathways in three-dimensional contexts. J Natl Cancer Inst 2002, 94:1494-1503
9. Mintz B, Illmensee K: Normal genetically mosaic mice produced from malignant teratocarcinoma cells. Proc Natl Acad Sci USA 1975, 72:3585-3589
10. Dolberg DS, Bissell MJ: Inability of Rous sarcoma virus to cause sarcomas in the avian embryo. Nature 1984, 309:552-556
11. Dolberg DS, Hollingsworth R, Hertle M, Bissell MJ: Wounding and its role in RSV-mediated tumor formation. Science 1985, 230:676-678
12. Kulesa PM, Kasemeier-Kulesa JC, Teddy JM, Margaryan NV, Seftor EA, Seftor RE, Hendrix MJ: Reprogramming metastatic melanoma cells to assume a neural crest cell-like phenotype in an embryonic microenvironment. Proc Natl Acad Sci USA 2006, 103:3752-3757
13. Myers CA, Schmidhauser C, Mellentin-Michelotti J, Fragoso G, Roskelley CD, Casperson G, Mossi R, Pujuguet P, Hager G, Bissell MJ: Characterization of BCE-1, a transcriptional enhancer regulated by prolactin and extracellular matrix and modulated by the state of histone acetylation. Mol Cell Biol 1998, 18:2184-2195
14. Plachot C, Lelievre SA: DNA methylation control of tissue polarity and cellular differentiation in the mammary epithelium. Exp Cell Res 2004, 298:122-132
15. Pujuguet P, Simian M, Liaw J, Timpl R, Werb Z, Bissell MJ: Nidogen-1 regulates laminin-1-dependent mammary-specific gene expression. J Cell Sci 2000, 113:849-858
16. Debnath J, Muthuswamy SK, Brugge JS: Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. Methods 2003, 30:256-268
17. Liu H, Radisky DC, Wang F, Bissell MJ: Polarity and proliferation are controlled by distinct signaling pathways downstream of PI3-kinase in breast epithelial tumor cells. J Cell Biol 2004, 164:603-612
18. Briand P, Nielsen KV, Madsen MW, Petersen OW: Trisomy 7p and malignant transformation of human breast epithelial cells following epidermal growth factor withdrawal. Cancer Res 1996, 56:2039-2044
19. Walsh DA, Perkins JP, Krebs EG: An adenosine 3′,5′- monophosphate-dependant protein kinase from rabbit skeletal muscle. J Biol Chem 1968, 243:3763-3765
20. Ashall F, Sullivan N, Puck TT: Specificity of the cAMP-induced gene exposure reaction in CHO cells. Proc Natl Acad Sci USA 1988, 85:3908-3912
21. Schonberg S, Patterson D, Puck TT: Resistance of Chinese hamster ovary cell chromatin to endonuclease digestion. I. Reversal by cAMP. Exp Cell Res 1983, 145:57-62
22. Kim S, Harris M, Varner JA: Regulation of integrin alpha vbeta 3-mediated endothelial cell migration and angiogenesis by integrin alpha5beta1 and protein kinase A. J Biol Chem 2000, 275:33920-33928
23. Kawasaki H, Springett GM, Mochizuki N, Toki S, Nakaya M, Matsuda M, Housman DE, Graybiel AM: A family of cAMP-binding proteins that directly activate Rapt Science 1998, 282:2275-2279
24. de Rooij J, Zwartkruis FJ, Verheijen MH, Cool RH, Nijman SM, Wittinghofer A, Bos JL: Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP. Nature 1998, 396:474-477
25. Christensen AE, Selheim F, de Rooij J, Dremier S, Schwede F, Dao KK, Martinez A, Maenhaut C, Bos JL, Genieser HG, Doskeland SO: cAMP analog mapping of Epad and cAMP kinase. Discriminating analogs demonstrate that Epac and cAMP kinase act synergistically to promote PC-12 cell neurite extension. J Biol Chem 2003, 278:35394-35402
26. Kopperud R, Krakstad C, Selheim F, Doskeland SO: cAMP effector mechanisms. Novel twists for an 'old' signaling system. FEBS Lett 2003, 546:121-126
27. Maniotis AJ, Chen CS, Ingber DE: Demonstration of mechanical connections between integrins, cytoskeletal filaments, and nucleoplasm that stabilize nuclear structure. Proc Natl Acad Sci USA 1997, 94:849-854
28. Ingber DE, Tensegrity I: Cell structure and hierarchical systems biology. J Cell Sci 2003, 116:1157-1173
29. Roskelley CD, Bissell MJ: The dominance of the microenvironment in breast and ovarian cancer. Semin Cancer Biol 2002, 12:97-104
30. Lin AY, Maniotis AJ, Valyi-Nagy K, Majumdar D, Setty S, Kadkol S, Leach L, Pe'er J, Folberg R: Distinguishing fibrovascular septa from vasculogenic mimicry patterns. Arch Pathol Lab Med 2005, 129:884-892
31. Ioachim E, Charchanti A, Briasoulis E, Karavasilis V, Tsanou H, Arvanitis DL, Agnantis NJ, Pavlidis N: Immunohistochemical expression of extracellular matrix components tenascin, fibronectin, collagen type IV and laminin in breast cancer: their prognostic value and role in tumour invasion and progression. Eur J Cancer 2002, 38:2362-2370
32. Ioachim E, Michael M, Stavropoulos NE, Kitsiou E, Salmas M, Malamou-Mitsi V: A clinicopathological study of the expression of extracellular matrix components in urothelial carcinoma. BJU Int 2005, 95:655-659
33. George EL, Baldwin HS, Hynes RO: Fibronectins are essential for heart and blood vessel morphogenesis but are dispensable for initial specification of precursor cells. Blood 1997, 90:3073-3081
34. George EL, Georges-Labouesse EN, Patel-King RS, Rayburn H, Hynes RO: Defects in mesoderm, neural tube and vascular development in mouse embryos lacking fibronectin. Development 1993, 119:1079-1091
35. Schor SL, Schor AM, Grey AM, Rushton G: Foetal and cancer patient fibroblasts produce an autocrine migration-stimulating factor not made by normal adult cells. J Cell Sci 1988, 90:391-399
36. Schor SL, Haggie JA, Durning P, Howell A, Smith L, Sellwood RA, Crowther D: Occurrence of a fetal fibroblast phenotype in familial breast cancer. Int J Cancer 1986, 37:831-836
37. Castellani P, Viale G, Dorcaratto A, Nicolo G, Kaczmarek J, Querze G, Zardi L: The fibronectin isoform containing the ED-B oncofetal domain: a marker of angiogenesis. Int J Cancer 1994, 59:612-618
38. Kaczmarek J, Castellani P, Nicolo G, Spina B, Allemanni G, Zardi L: Distribution of oncofetal fibronectin isoforms in normal, hyperplastic and neoplastic human breast tissues. Int J Cancer 1994, 59:11-16
39. Labat-Robert J: Thirty years after fibronectin discovery: role in malignant transformation and in ageing. J Soc Biol 2004, 198:287-291
40. Midulla M, Verma R, Pignatelli M, Ritter MA, Courtenay-Luck NS, George AJ: Source of oncofetal ED-B-containing fibronectin: implications of production by both tumor and endothelial cells. Cancer Res 2000, 60:164-169
41. Zardi L, Carnemolla B, Siri A, Petersen TE, Paolella G, Sebastio G, Baralle FE: Transformed human cells produce a new fibronectin isoform by preferential alternative splicing of a previously unobserved exon. EMBO J 1987, 6:2337-2342
42. Picardo M, Schor SL, Grey AM, Howell A, Laidlaw I, Redford J, Schor AM: Migration stimulating activity in serum of breast cancer patients. Lancet 1991, 337:130-133
43. Durning P, Schor SL, Sellwood RA: Fibroblasts from patients with breast cancer show abnormal migratory behaviour in vitro. Lancet 1984, 2:890-892
44. Schor SL, Ellis IR, Jones SJ, Baillie R, Seneviratne K, Clausen J, Motegi K, Vojtesek B, Kankova K, Furrie E, Sales MJ, Schor AM, Kay RA: Migration-stimulating factor: a genetically truncated onco-fetal fibronectin isoform expressed by carcinoma and tumor-associated stromal cells. Cancer Res 2003, 63:8827-8836